Find the tracker for what you take.
One page per medication or peptide: what PepLabo records for it, its status with sources, and answers to the questions people ask first.
GLP-1 brands
Ozempic®
Semaglutide pen: weekly rhythm, site rotation and check-ins.
Ozempic® trackerWegovy®
Weekly semaglutide injection for weight management.
Wegovy® trackerWegovy® pill
Once-daily oral semaglutide for weight management.
Wegovy® pill trackerRybelsus®
Once-daily oral semaglutide for type 2 diabetes.
Rybelsus® trackerMounjaro®
Weekly tirzepatide injection, by pen or vial.
Mounjaro® trackerZepbound®
Weekly tirzepatide for weight management and sleep apnoea.
Zepbound® trackerSaxenda®
Once-daily liraglutide pen for weight management.
Saxenda® trackerVictoza®
Once-daily liraglutide pen for type 2 diabetes.
Victoza® trackerTrulicity®
Weekly dulaglutide pen for type 2 diabetes.
Trulicity® trackerFoundayo™
Once-daily orforglipron tablet, approved in the US in 2026.
Foundayo™ tracker
GLP-1 substances
Semaglutide
Ozempic®, Wegovy® and Rybelsus®: one substance, several forms.
Semaglutide trackerTirzepatide
Mounjaro® and Zepbound®: weekly GIP and GLP-1 injections.
Tirzepatide trackerLiraglutide
Victoza®, Saxenda® and generic pens, once a day.
Liraglutide trackerOrforglipron
Oral non-peptide GLP-1 agonist; Foundayo™ in the US.
Orforglipron tracker
Investigational, not approved
Retatrutide
Investigational GIP, GLP-1 and glucagon agonist; not approved.
Retatrutide trackerCagriSema
Investigational cagrilintide with semaglutide; filed with the FDA.
CagriSema trackerAmycretin
Investigational GLP-1 and amylin agonist in phase 3.
Amycretin tracker
Peptides
BPC-157
Not an approved medicine; research is mostly in animals.
BPC-157 trackerTB-500
Thymosin beta-4 fragment; not an approved medicine.
TB-500 trackerIpamorelin
Growth hormone secretagogue; reached phase 2, not approved.
Ipamorelin trackerCJC-1295
GHRH analogue, with or without DAC; not approved.
CJC-1295 trackerSermorelin
GHRH(1-29); once approved in the US as Geref, discontinued.
Sermorelin trackerTesamorelin
EGRIFTA SV® and EGRIFTA WR™; FDA approved for HIV lipodystrophy.
Tesamorelin trackerPT-141 (bremelanotide)
Approved in the US as Vyleesi® for one specific use.
PT-141 trackerGHK-Cu
Copper peptide used in cosmetics; no approved injectable medicine.
GHK-Cu trackerSemax
ACTH(4-10) analogue; registered in Russia, not in the US or EU.
Semax trackerSelank
Tuftsin-based peptide; approved in Russia, not in the US or EU.
Selank trackerNAD+
A coenzyme in every cell; human studies of direct NAD+ are small.
NAD+ tracker
Ozempic®, Wegovy®, Rybelsus®, Saxenda® and Victoza® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, Trulicity® and Foundayo™ are trademarks of Eli Lilly and Company. EGRIFTA SV® and EGRIFTA WR™ are trademarks of Theratechnologies Inc. Vyleesi® is a trademark of its owner. PepLabo is not affiliated with or endorsed by any of these companies.
Set up your lab tonight.
It takes a few minutes. Pep will be waiting.